Literature DB >> 10728748

Prevalence of anti-protein S antibodies in patients with systemic lupus erythematosus.

K S Song1, Y S Park, H K Kim.   

Abstract

OBJECTIVE: To determine the prevalence of circulating anti-protein S (anti-PS) antibodies in association with PS deficiency in patients with systemic lupus erythematosus (SLE).
METHODS: Plasma was obtained from blood samples collected from 27 patients with SLE (5 men, 22 women; mean +/- SD age 32 +/- 10 years). Anti-PS antibodies were detected by immunoblotting according to a previously described method. Levels of free and total PS antigen were measured by enzyme-linked immunosorbent assay. PS activity was assayed by a clotting method. Levels of C4b binding protein (C4bBP) were measured by latex immunoassay.
RESULTS: Among 27 patients with SLE, 19 (70.4%) had PS activity, and 12 (44.4%) had PS free antigen below the lower limit established for a normal population (mean -2SD). There was good correlation between PS activity and levels of PS free antigen (r = 0.851, P < 0.001), PS total antigen (r = 0.743, P < 0.001), and C4bBP (r = 0.597, P = 0.001). Circulating anti-PS antibodies and antiphospholipid antibodies (aPL) (IgG type) were detected in 7 (25.9%) and 14 (51.9%) of the 27 patients with SLE, respectively. Only 1 patient (3.7%) had both anti-PS antibodies and aPL. PS activities in patients who were positive for anti-PS antibodies (mean 38.7%) tended to be lower than those in patients who were negative for anti-PS antibodies (mean 54.9%), but the difference was not statistically significant.
CONCLUSION: Anti-PS antibodies, independently of aPL, may play a role in the occurrence of PS deficiency in some patients with SLE, with possible effects on the function of PS that do not change the levels of PS antigens.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10728748     DOI: 10.1002/1529-0131(200003)43:3<557::AID-ANR11>3.0.CO;2-O

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  15 in total

Review 1.  TAM receptor signaling and autoimmune disease.

Authors:  Carla V Rothlin; Greg Lemke
Journal:  Curr Opin Immunol       Date:  2010-10-26       Impact factor: 7.486

Review 2.  Diagnosis of the antiphospholipid syndrome: how far to go?

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

3.  Decreased protein S activity is related to the disease activity of Behcet's disease.

Authors:  Seong Ryul Kwon; Mie Jin Lim; Shin Goo Park; Yeon Sook Moon; Won Park
Journal:  Rheumatol Int       Date:  2006-09-13       Impact factor: 2.631

Review 4.  Biology of the TAM receptors.

Authors:  Greg Lemke
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-11-01       Impact factor: 10.005

Review 5.  Immunobiology of the TAM receptors.

Authors:  Greg Lemke; Carla V Rothlin
Journal:  Nat Rev Immunol       Date:  2008-05       Impact factor: 53.106

Review 6.  TAM receptor signaling in immune homeostasis.

Authors:  Carla V Rothlin; Eugenio A Carrera-Silva; Lidia Bosurgi; Sourav Ghosh
Journal:  Annu Rev Immunol       Date:  2015-01-14       Impact factor: 28.527

7.  Autoimmune diseases and venous thromboembolism: a review of the literature.

Authors:  Bengt Zöller; Xinjun Li; Jan Sundquist; Kristina Sundquist
Journal:  Am J Cardiovasc Dis       Date:  2012-07-25

Review 8.  What causes the antiphospholipid syndrome?

Authors:  J T Merrill
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

Review 9.  Dendritic cells in systemic lupus erythematosus.

Authors:  Heather M Seitz; Glenn K Matsushima
Journal:  Int Rev Immunol       Date:  2010-04       Impact factor: 5.311

10.  TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus.

Authors:  Chang-Hee Suh; Brendan Hilliard; Sophia Li; Joan T Merrill; Philip L Cohen
Journal:  Arthritis Res Ther       Date:  2010-07-16       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.